Oculus Innovative Sciences Announces Licensing of Microcyn(R)-Based Products in Mexico, South/Central America and Caribbean Countries to More Pharma With $5.1 Million Up Front Payment Aug 9, 2012
Oculus Innovative Sciences Reports Record Revenues of $4.1 Million for the First Quarter of Fiscal 2013 Aug 2, 2012
Oculus Innovative Sciences Announces Fiscal First Quarter 2013 Financial Results and Conference Call Jul 25, 2012
Oculus Innovative Sciences Receives Chinese SFDA Regulatory Approval of Microcyn(R) Hydrogel Jul 10, 2012
AmDerma and Oculus Innovative Sciences Enter Into Multi-Country Agreement to Develop and Commercialize Novel Microcyn(R)-Based Drugs for Major Dermatological Conditions Jun 25, 2012
Photo Release -- Napa Valley Nutritionals Launches Two New Glucorein(TM) Chlorogenic-Acid Products -- Robusta/Arabica Blend and Brazilian Decaf Jun 14, 2012
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2012 Financial Results and Conference Call May 24, 2012
Oculus Innovative Sciences Prepares to Initiate Clinical Study for Use of Microcyn(R) Hydrogel in Management of Scars Based Upon FDA-Reviewed Protocol May 11, 2012
Oculus Innovative Sciences Microcyn(R) Technology to be Showcased at the Columbia University 10th Annual Innovations in Complex Vascular & Endovascular Interventions in New York City on May 10-11, 2012 May 9, 2012
